Search research articles
Contact Us
Filters
Showing results (11-20 of 76) with videos related to
Page
of 8
Sort By:
Drug Discovery Today
|
April 12, 2011
Histone acetyltransferases are crucial regulators in NF-κB mediated inflammation
Massimo Ghizzoni, Hidde J Haisma, Harm Maarsingh, et al.
Pharmaceutical Research
|
April 3, 2003
Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate
María José Fonseca, Joycelyn C Jagtenberg, Hidde J Haisma, et al.
The Journal of Gene Medicine
|
August 5, 2014
Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL)
Mohammad Arabpour, Klaas Poelstra, Wijnand Helfrich, et al.
Nuclear Medicine Communications
|
September 5, 2008
Tumor-specific activation of prodrugs: is there a role for nuclear medicine?
Inês F Antunes, Hidde J Haisma, Erik F J de Vries
British Journal of Sports Medicine
|
January 17, 2013
Gene doping: an overview and current implications for athletes
Toon van der Gronde, Olivier de Hon, Hidde J Haisma, et al.
Bioorganic & Medicinal Chemistry
|
July 14, 2012
Anacardic acid derived salicylates are inhibitors or activators of lipoxygenases
Rosalina Wisastra, Massimo Ghizzoni, André Boltjes, et al.
Bioorganic & Medicinal Chemistry
|
July 27, 2010
Improved inhibition of the histone acetyltransferase PCAF by an anacardic acid derivative
Massimo Ghizzoni, André Boltjes, Chris de Graaf, et al.
Biochemical Pharmacology
|
June 5, 2003
Cytosolic beta-glycosidases for activation of glycoside prodrugs of daunorubicin
Michelle de Graaf, Herbert M Pinedo, Razi Quadir, et al.
Journal of Drug Targeting
|
November 26, 2016
Receptor-specific TRAIL as a means to achieve targeted elimination of activated hepatic stellate cells
Mohammad Arabpour, Robbert H Cool, Klaas Nico Faber, et al.
Current Pharmaceutical Design
|
June 8, 2002
Beta-glucuronidase-mediated drug release
Michelle de Graaf, Epie Boven, Hans W Scheeren, et al.
Page
of 8
Search research articles
Search
Showing results (11-20 of 76) with videos related to
Sort By:
Page
of 8
Drug Discovery Today
|
April 12, 2011
Histone acetyltransferases are crucial regulators in NF-κB mediated inflammation
Massimo Ghizzoni, Hidde J Haisma, Harm Maarsingh, et al.
Pharmaceutical Research
|
April 3, 2003
Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate
María José Fonseca, Joycelyn C Jagtenberg, Hidde J Haisma, et al.
The Journal of Gene Medicine
|
August 5, 2014
Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL)
Mohammad Arabpour, Klaas Poelstra, Wijnand Helfrich, et al.
Nuclear Medicine Communications
|
September 5, 2008
Tumor-specific activation of prodrugs: is there a role for nuclear medicine?
Inês F Antunes, Hidde J Haisma, Erik F J de Vries
British Journal of Sports Medicine
|
January 17, 2013
Gene doping: an overview and current implications for athletes
Toon van der Gronde, Olivier de Hon, Hidde J Haisma, et al.
Bioorganic & Medicinal Chemistry
|
July 14, 2012
Anacardic acid derived salicylates are inhibitors or activators of lipoxygenases
Rosalina Wisastra, Massimo Ghizzoni, André Boltjes, et al.
Bioorganic & Medicinal Chemistry
|
July 27, 2010
Improved inhibition of the histone acetyltransferase PCAF by an anacardic acid derivative
Massimo Ghizzoni, André Boltjes, Chris de Graaf, et al.
Biochemical Pharmacology
|
June 5, 2003
Cytosolic beta-glycosidases for activation of glycoside prodrugs of daunorubicin
Michelle de Graaf, Herbert M Pinedo, Razi Quadir, et al.
Journal of Drug Targeting
|
November 26, 2016
Receptor-specific TRAIL as a means to achieve targeted elimination of activated hepatic stellate cells
Mohammad Arabpour, Robbert H Cool, Klaas Nico Faber, et al.
Current Pharmaceutical Design
|
June 8, 2002
Beta-glucuronidase-mediated drug release
Michelle de Graaf, Epie Boven, Hans W Scheeren, et al.
Page
of 8